Expert Interview
Discussing the trends in the NK cell landscape for the future of CART therapies, specifically FATE therapeutics and their iPSC-Derived cell products
Ticker(s): FATE, SNYInstitution: University of Central Florida
- Associate Professor of Medicine at the Burnett School of Biomedical Sciences at University of Central Florida.
- Co-founder of Cyto-Sen Therapeutics, now Kiadis, a Sanofi company which specializes in innate immunity with emphasis on cell biology of Natural Killer (NK) cells in the context of immunotherapy for treatment of cancer.
- Laboratory has developed a nanoparticle-based platform for NK cell expansion that is simple, safe, economical and effective.
Please describe your background and current practice setting
Added By: ben_adminWhat benefits could allogeneic T cell treatments have over autologous T cells?
Added By: ben_adminWhat makes NK cells promising as a CART therapy?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
